FY21. To 1 - manufacture of cgmp methamphetamine HCL for IV injection. POP 9/18/21-1/17/22.
Ended Awarded Last action
- Contract number
- 75N95021F00001
- Awardee
-
Murty Pharmaceuticals, Inc. UEI DNJBTJ3XBQM6
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $312,612
Award facts
- Opportunity
-
- Development & Manufacture of Pharmaceutical Products for the Treatment of Substance Abuse Disorder Pre-Solicitation · 75N95020R00036 · Posted Jun 26, 2020
- Development & Manufacture of Pharmaceutical Products for the Treatment of Substance Abuse Disorder Pre-Solicitation · Posted Feb 12, 2021
- Contract value 100% obligated
- $312,612.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Lexington, KY 40509, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $28,223 | |
| Change Order | -$6,390 | |
| Change Order | $0 | |
| Change Order | -$18,308 | |
| Original award | $309,087 |
About this award
This is a cost-plus-fixed-fee delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services. The $312,612.00 contract is for the manufacture of Good Manufacturing Practice (GMP) methamphetamine hydrochloride for intravenous injection, to support NIDA's research and development efforts in developing treatments for substance use disorders. The work will be performed by Murty Pharmaceuticals, Inc., a minority-owned small disadvantaged business, at their facility in Lexington, Kentucky. This order is issued under NIDA's $7 million indefinite delivery contract with Murty for pharmaceutical development and manufacturing, as well as their $45 million IDIQ contract with the National Institutes of Health for drug formulation and manufacturing services. The contract does not utilize any small business set-asides.
Quick answers
Who was awarded contract 75N95021F00001?
75N95021F00001 was awarded to Murty Pharmaceuticals, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 18, 2021.
How much is contract 75N95021F00001 worth?
The government has obligated $312,612 on 75N95021F00001.
Is contract 75N95021F00001 an order under another contract?
Yes. 75N95021F00001 is a delivery order under 75N95021D00024, an indefinite delivery contract.
Was contract 75N95021F00001 competed?
The extent of competition for 75N95021F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award